Business
Health Canada Accepts for Review Medexus's New Drug Submission for Topical Terbinafine
Topical terbinafine has been widely used in other markets to treat fungal nail infections If a...
About this update from Medexus Pharmaceuticals Inc.
[{"type":"text","content":"Health Canada Accepts for Review Medexus's New Drug Submission for Topical TerbinafineTopical terbinafine has been widely used in other markets to treat fungal nail infectionsIf and when approved, the product will enter the topical fungicides market that is estimated to be C$88 million on an annual basis*Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 8, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced that Health Canada recently accepted for review Medexus's new drug submission, or NDS, for terbinafine hydrochloride nail lacquer to treat fungal nail infections.\"Health Canada's commitment to review our NDS brings us a step closer to making topical terbinafine a viable treatment option for Canadians,\" said Richard Labelle, Medexus's General Manager-Canadian Operations. \"Topical terbinafine is an excellent strategic fit for our leading allergy/dermatology business, and we look forward to putting our institutional knowledge to work as we target a commercial launch in the first half of calendar year 2025.\"Topical terbinafine has been widely used in other markets to treat fungal nail infections. Medexus's NDS for topical terbinafine seeks Health Canada approval for a distinctive once-a week treatment regimen. If and when approved, the product will enter the Canadian topical fungicides market that is estimated to be C$88 million on an annual basis.** Source: IQVIA Canadian drugstore and hospital purchases, September 2023 MAT.About MedexusMedexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. For more information about Medexus and its product portfolio, please see the company's corporate website at www.medexus.com and its filings on SEDAR+ at www.sedarplus.com.ContactsKen d'Entremont | CEO, Medexus PharmaceuticalsTel: 905-676-0003 | Email: [email protected] Konrad | CFO, Medexus PharmaceuticalsTel: 312-548-3139 | Email: [email protected] statementsCertain statements made in this news release contain forward-looking information within the meaning of applicable securities laws, also known and/or ...